

Original Research Article

doi: <https://doi.org/10.20546/ijcrbp.2018.504.005>

The Antioxidant Properties of *Momordica charantia* Extract and its Protective Activities against *In Vitro* Mercury Intoxication

E. E. Orji*, A. E. Falodun and F. I. Jegede

Department of Science Technology and Glass and Ceramics Technology, Federal Polytechnic, Ado-Ekiti, Nigeria

*Corresponding author.

Article Info

Date of Acceptance:
30 March 2018

Date of Publication:
06 April 2018

Keywords

Antioxidant
Homogenate
Intoxicant
Mercuric chloride
Momordica charantia

ABSTRACT

Momordica charantia is a potent modulator of antioxidant and liver function indices. This research examines the antioxidant status of the extract and its protective effect on hepatic and renal system *in vitro*. The extract scavenges DPPH radicals in a concentration dependent manner and the reducing power of the extract increases with concentration. Thus, the homogenate were divided into five groups for the experiment. The group 1 is the control that has no intoxicant and extract. The group 2 contains homogenate and intoxicant while group 3 contains homogenate, intoxicant in dose dependent manner of 100ug/ml, 500ug/ml, and 1000ug/ml and likewise group 4, but no intoxicant. In group 5, the homogenate and intoxicant were treated with quercetin, a chelator used treatment of Hg poisoning. According to result, the extract of *Momordica charantia* chelates iron in a concentration dependent manner, thus showing that the extract has iron chelating activity and acting as primary antioxidant. This study indicates that Hg administered group significantly reduced the concentration of kidney-sodium transport and decreased the activities of AST, ALT, GGT, leading to enzymes inactivation and degradation. Treatments with *Momordica charantia* extract help in bringing it back to near normal.

Introduction

Momordica charantia L. commonly known as bitter gourd is an economically important medicinal plant belonging to the family Cucurbitaceae. Two varieties of this plant are cultivated in India. *M. charantia* var. *charantia* with large fruits which are fusiform in shape are *M. charantia* var. *muricata*, which are identified by small, round fruit

(Nadkarni, 2007). The immature fruits are eaten as vegetables and are a good source of vitamin C, vitamin A and phosphorus and iron. The bitter flavour of both the varieties is due to the alkaloid momordicine produced in fruits and leaves. Fruits and seeds of bitter gourd possess medicinal properties such as anti-HIV, anti-ulcer, anti-inflammatory, anti-leukemic, antimicrobial, anti tumor and last but not the least the important anti

diabetic property (Ng, et al., 1994; She et al., 1996; Grover and Yadav, 2004; Soundararajan et al., 2012). It contains an array of biologically active plant chemicals including triterpens, proteins, steroids, alkaloids, saponins, flavonoids and acids due to which plant possesses anti-fungal, anti-bacterial, anti-parasitic, anti-viral, anti-fertility, anti-tumorous, hypoglycaemic and anti-carcinogenic properties (Kumar et al., 2010). Fruits are used as traditional medication to cure various diseases like: rheumatism, gout, worms, colic, disease of liver and spleen. It is also found useful in the treatment of cancer and diabetes. It is a potent hypoglycaemic agent due to alkaloids and insulin like peptides and a mixture of steroidal saponins known as charantin (Agrawal and Kamal, 2004). The plant is a climbing perennial with elongated fruit that resembles a warty gourd or cucumber. The unripe fruit is white or green in colour and has a bitter taste that becomes more pronounced as the fruit ripens. It is a monoecious climber found throughout the country often under cultivation, up to an altitude of 1500 m. It is a slender climbing annual vine with long-stalked leaves and yellow, solitary male and female flowers borne in the leaf axils.

Materials and methods

Experimental design

Homogenates were divided into 5 major groups for the experiment.

Group 1: Control

Group 2: HgCl₂ administered group (Homogenate + toxicant)

Group 3: HgCl₂ administered and extract treated groups (Homogenate + Toxicant + Extract).

a. Homogenate + Toxicant + Extract (100 µg/ml)

b. Homogenate + Toxicant + Extract (500 µg/ml)

c. Homogenate + Toxicant + Extract (1000 µg/ml)

Group 4: extract administered groups (Homogenate + Extract).

a. Homogenate + Extract (100 µg/ml)

b. Homogenate + Extract (500 µg/ml)

c. Homogenate + Extract (1000 µg/ml)

Group 5: HgCl₂ administered and quercetin treated group (Homogenate + Toxicant + quercetin)

Test were performed in triplicate, test samples were incubated at 37°C for 25 min and then used for biochemical assays.

Procedure: Male albino rats (Wistar strain) 200±20g were used for the study. Rats were anaesthetized by cervical dislocation and sacrificed loss of consciousness. The livers and kidney were excised, washed in ice cold 1.15% potassium chloride solution, blotted with filter paper and weighed. They were homogenized in 5 % w/v 0.1M sodium phosphate buffer (pH 7.4) using a Teflon homogenizer. The resulting homogenates were stored at -20°C and then used for biochemical analysis. The plant extract was air dried for 21 days at room temperature before soaking it in water for 72 hours, and freeze dried to obtain the extract used for the analysis.

Assay of reducing power activity

Extract (0.5 ml) was mixed with 1.25 ml each of phosphate buffer and potassium ferricyanide (C₆N₆FeK₃). The mixture was incubated at 50°C for 20 min. Trichloroacetic acid (1.25 ml) was then added and the mixture centrifuged at 3000 rpm for 10 min. Thereafter, 1.25 ml of the upper layer of the solution was mixed with 1.25 ml of distilled water and 0.25 ml of FeCl₃. The absorbance was read at 700 nm. Higher absorbance of the reaction mixture indicates greater reductive potential.

Assay of DPPH (1, 1-diphenyl-2-picrylhydrazyl) radical scavenging activity

Exactly 1 ml of 0.3mM DPPH prepared in methanol was added to 1 ml of extract of various concentrations (100 g/ml-500µg/ml) and allowed to react at room temperature for 30 min. The reaction mixture was vortexed thoroughly and left in the dark at room temperature for 30 min. The absorbance of the mixture was measured spectrophotometrically at 517nm and the percentage scavenging activity was calculated using the formula below.

$$\% \text{ Scavenging activity} = ((Ac - As)/Ac) \times 100$$

Where, Ac is the absorbance of control and As the absorbance of the extract.

Assay for Iron chelating activity

The iron chelating activity was determined according to the method of Haro-Vicente et al. (2006). Extract (1 ml) was added to 100 µl of 1 mM FeSO₄.7H₂O. The reaction mixture was left at room temperature for 2 min. After which 0.5 ml of 0.5 mM 1, 10-phenanthroline was added and the mixture was incubated for 10 min at room temperature. The absorbance was read at 510 nm. The Fe²⁺ chelating capacity was calculated thus:

$$\text{Fe}^{2+} \text{ chelating activity (\%)} = [(Ac - As) / Ac] \times 100$$

Evaluation of aspartate amino transferase (AST) activity

Diluted sample (0.1ml) was mixed with 0.5 ml of R1 [phosphate buffer (100 mmol/L, pH 7.4), L-aspartate (100 mmol/L), and α-oxoglutarate (2 mmol/L)] and the mixture incubated for 30 min at 37°C after which 0.5 ml of R2 [2, 4-dinitrophenylhydrazine (2 mmol/L)] was added to the reaction mixture and allowed to stand for another 20 min at 25°C. Then, 5.0 ml of NaOH (0.4 mol/L) was added and the absorbance was read against the reagent blank after 5 min at 546 nm. The activity of AST in homogenate was obtained following the extrapolation of absorbance value on AST standard curve.

Evaluation of alanine amino transferase (ALT) activity

2, 4-dinitrophenylhydrazine (2.0mmol/l) was added and the mixture incubated again at 20°C for Reagent1 (0.5 ml) containing Phosphate buffer (100 mmol/l, pH 7.4), L-alanine (200 mmol/l) and α-oxoglutarate (2.0 mol/l) was added to a test tube already containing 0.1 ml of serum sample and the mixture was incubated at 37°C for 30 min. Then, 0.5ml of R2 containing 20 min. Finally, 5 ml of NaOH was added. The mixture was allowed to

stand for 5 min at room temperature and the absorbance was read at 546nm. The activity of ALT in the homogenate was obtained from a standard curve.

Evaluation of gamma-glutamyl transferase (GGT) activity

The assay was conducted using a Randox kit manual. Using a water-bathe set at 37°C for the incubation of the reaction, the reaction is constituted of 100µl of the sample extract 1000µl of the reagent at a pH of 8.25 using tris-buffer of 100mmol/l concentration. The reagent contains glycylglycine (100mmol/l) and L-α-glutamyl-3-carboxy-4-nitroanilide (2.9 mmol/l). The absorbance of the mixture was read at 405nm.

Calculation

To calculate the GGT activity the following formula was used:

$$U/L = 1158 \times A \text{ 405 nm/min.}$$

Results and discussion

The antioxidant activity of *Momordica charantia* extract scavenges DPPH radicals in concentration dependent manner (Fig. 2). This study shows that the extract has the proton donating ability and serves as free radical inhibitors or scavengers, acting as a primary antioxidant. The reducing power of the extract increased with increasing concentration (Fig. 3).

This is related to the ability of the antioxidant agent to transfer electron or H atom to oxidant or free radicals. Thus, antioxidant property of phenolics is due to their redox properties which allow them to act as hydrogen donors and singlet oxygen quenchers (Rice-Evans et al., 1996).

Generally, the chelating of iron is regarded as an antioxidant mechanism to prevent oxidative assault on biological macro molecules such as lipids, protein and nucleic acids. Free iron is a potential enhancer of

reactive oxygen species formation, as it leads to reduction of H₂O₂ and generation of highly aggressive hydroxyl radicals that can perpetuate the chain reaction. This study revealed that Hg-administered group significantly reduced the concentration of kidney-sodium transport which suggest kidney malfunction. However, treatment with the extract help in bringing it back to near normal, these indicated the hepato-renal-protective

attribute of *Momordica charantia* extract which could be traced to the natural compounds present in it. As presented in the figures below, the activities of ALT, AST, GGT and kidney-Sodium transport were significantly ($p < 0.05$) lowered in the groups exposed to mercury compared to values for control group (Figs. 4, 5, 6 and 7). Also, Hg-administered group significantly decreased activities of AST, ALT, and GGT.




Fig. 2: (A) Metal chelating activity of *Momordica charantia* extract and (B) DPPH. Values with different superscript in a column are significantly different ($p < 0.05$).




Fig. 3: Reducing power activity of *Momordica charantia* extract. Values with different superscript in a column are significantly different ($p < 0.05$).

Fig. 4: Effect of *Momordica charantia* extract on liver ALT activity.




Fig. 5: Effect of *Momordica charantia* extract on liver AST activity.




Fig. 6: Effect of *Momordica charantia* extract on liver GGT activity.




Fig. 7: Effect of *Momordica charantia* on kidney sodium concentration. Values with different superscript in a column are significantly different ($p < 0.05$).

Loss of activity of enzymes in the Hg administered group is a consequence of inactivation and degradation of enzyme and protein by Hg (Mercury), thus lowering enzyme activities. Present findings are in agreement with the findings of El-Demerdash (2001) who showed that HgCl intoxication significantly decreased ALT activity in rat. Hg is known to react with sulphhydryl group, the cell membrane and impair their function, which is possible the cause of inhibition of AST and ALT activities. Treatment with *Momordica charantia* extract significantly increased the level of activities of ALT, AST, and GGT level in the liver homogenates of the treated groups. Chelating agents or chelators such as dimercapol and quercetin used in treatment of mercury poisoning generally competes with endogenous sulphhydryl, carboxyl, amine, amide and phosphate group. This could be possible mechanism of the modulatory action of the extract.

Conflict of interest statement

Authors declare that they have no conflict of interest.

References

- Agrawal, M., Kamal, R., 2004. *In vitro* clonal propagation of *Momordica charantia* L. Ind. J. Biotech. 3, 426-430.
- El-Demerdash, F., 2001. Effects of selenium and mercury on the enzymatic activities and lipid peroxidation in brain, liver, and blood of rats. J. Environ. Sci. Health B. 36, 489-499.
- Grover, J. K., Yadav, S. P., 2004. Pharmacological actions and potential uses of *Momordica charantia*: A review. J. Ethnopharmacol. 93(1), 123-132.
- Kumar, D.S., Sharathnath, K.V., Yogeswaran, P., Harani, A., Sudhakar, K., Sudha, P., Banji, D., 2010. A medicinal potency of *Momordica charantia*. Int. J. Pharmaceut. Sci. Rev. Res. 1(2), 95.
- Lee-Huang, S., Huang, P. L., Chen, H. C., 1995. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene.

- 161(2), 151-156.
- Nadkarni, K.M., 2007. Indian Materia Medica. Vol. 1, Popular Prakashan Pvt. Ltd., Mumbai, India. pp.805-807.
- Ng, T. B., Liu, W. K., Sze, S. F., Yeung, H. W., 1994. Action of α -momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. *General Pharmacol.* 25(1), 75-77.
- Rice-Evans, C., Miller, N.J., Paganga, G., 1996. Structure–antioxidant activity relationships of flavonoids and phenolic acids. *Free Rad. Biol. Med.* 20, 933-956.
- Shi, H., Hiramatsu, M., Komatsu, M., Kayama, T., 1996. Antioxidant property of *Fructus momordicae* extract. *Biochem. Mol. Biol. Int.* 40(6), 1111-1121.

How to cite this article:

Orji, E.E., Falodun, A.E., Jegede, F.I., 2018. The Antioxidant properties of *Momordica charantia* extract and its protective activities against *in vitro* mercury intoxication. *Int. J. Curr. Res. Biosci. Plant Biol.* 5(4), 30-35. doi: <https://doi.org/10.20546/ijcrbp.2018.504.005>